Cargando…

Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro

COVID-19, which is caused by the emerging human coronavirus SARS-CoV-2, has become a global pandemic that poses a serious threat to human health. To date, no vaccines or specific antiviral drugs have been approved for the treatment of this disease in clinic. Herein, therapeutic antibodies for SARS-C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Xiaoyan, Zhou, Pengfei, Fan, Tiejiong, Wu, Yan, Zhang, Jing, Shi, Xiaoyue, Shang, Weijuan, Fang, Lijuan, Jiang, Xiaming, Shi, Jian, Sun, Yuan, Zhao, Shaojuan, Gong, Rui, Chen, Ze, Xiao, Gengfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351055/ https://www.ncbi.nlm.nih.gov/pubmed/32659292 http://dx.doi.org/10.1016/j.antiviral.2020.104868

Ejemplares similares

Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus
por: Pan, Xiaoyan, et al.
Publicado: (2020)

Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants
por: Wu, Yan, et al.
Publicado: (2023)

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
por: Passariello, Margherita, et al.
Publicado: (2021)

Equine immunoglobulin fragment F(ab’)(2) displays high neutralizing capability against multiple SARS-CoV-2 variants
por: Gupta, Divya, et al.
Publicado: (2022)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

Prophylactic Efficacy of Equine Immunoglobulin F(ab′)(2) Fragments Against Feline Parvovirus
por: Liu, Jinfeng, et al.
Publicado: (2021)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice
por: Song, Shuo, et al.
Publicado: (2022)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
por: Liu, Zheng, et al.
Publicado: (2022)

Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines
por: Dickey, Thayne H., et al.
Publicado: (2023)

Production and purification of polyclonal antibody against F(ab')2 fragment of human immunoglobulin G
por: Nasiri, Hadi, et al.
Publicado: (2017)

Equine immunoglobulin F(ab')(2) fragments protect cats against feline calicivirus infection
por: Cui, Zhanding, et al.
Publicado: (2019)

Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response
por: Lin, Ting-Wei, et al.
Publicado: (2022)

Identification of Closed Linear Epitopes in S1-RBD and S2-HR1/2 of SARS-CoV-2 Spike Protein Able to Induce Neutralizing Abs
por: Watanabe, Yoshihiro, et al.
Publicado: (2023)

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
por: Pan, Xiaoyan, et al.
Publicado: (2021)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine
por: Li, Chia-Jung, et al.
Publicado: (2023)

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
por: Passariello, Margherita, et al.
Publicado: (2023)

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
por: Junker, Daniel, et al.
Publicado: (2022)

Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies
por: Salinas, Facundo, et al.
Publicado: (2022)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
por: Shah, Masaud, et al.
Publicado: (2020)

Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
por: Errico, John M., et al.
Publicado: (2021)

Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus
por: Parrington, Helen M., et al.
Publicado: (2023)

Equine Immunoglobulin and Equine Neutralizing F(ab′)(2) Protect Mice from West Nile Virus Infection
por: Cui, Jiannan, et al.
Publicado: (2016)

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
por: Zhang, Jing, et al.
Publicado: (2022)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2
por: Lei, Hong, et al.
Publicado: (2020)

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)(2) fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study
por: Farizano Salazar, Diego H., et al.
Publicado: (2022)

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
por: Luo, Deyan, et al.
Publicado: (2022)

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics
por: Zhao, Shaojuan, et al.
Publicado: (2021)

A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
por: Wang, Xiaofei, et al.
Publicado: (2022)

Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization
por: Noy-Porat, Tal, et al.
Publicado: (2023)

Performance Evaluation of RapiSure (EDGC) COVID-19 S1 RBD IgG/Neutralizing Ab Test for the Rapid Detection of SARS-CoV-2 Antibodies
por: Kim, Ha Nui, et al.
Publicado: (2023)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
por: Chen, Yuxin, et al.
Publicado: (2021)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
por: Bertoglio, Federico, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tbnp4hg4lhao963s4o1ctvii43